Here are the 10-K annual reports from Marker Therapeutics, Inc. (MRKR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRKR filings page.
Marker Therapeutics files its annual report outlining progress on its MAR‑T cell immunotherapy pipeline and partnerships. The company is advancing MT‑601 for relapsed lymphoma (APOLLO trial) and pancreatic cancer (PANACEA), plus an off‑the‑shelf MT‑401 program for AML and MDS.
Grants from CPRIT and NIH/SBIR, including a $9.5 million CPRIT pancreatic cancer award and a $2 million NIH SBIR grant, are helping fund MT‑601 without diverting resources from lymphoma. Marker shifted manufacturing from Cell Ready to BCM and Cellipont to prepare for larger MT‑601 trials.
As of June 30, 2025, non‑affiliate equity market value was about $17.3 million, based on a $1.53 Nasdaq price. Shares outstanding were 16,673,127 as of March 16, 2026. The report also details extensive licensing, royalty, and regulatory frameworks around its MAR‑T platform.